These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 8297715)
1. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid. Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715 [TBL] [Abstract][Full Text] [Related]
2. Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro. Sen S; Erba E; D'Incalci M; Bottero F; Canevari S; Tomassetti A Br J Cancer; 1996 Feb; 73(4):525-30. PubMed ID: 8595169 [TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Smith SG; Lehman NL; Moran RG Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626 [TBL] [Abstract][Full Text] [Related]
4. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells. Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools. Kwok JB; Tattersall MH Biochem Pharmacol; 1991 Jul; 42(3):507-13. PubMed ID: 1859463 [TBL] [Abstract][Full Text] [Related]
6. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells. Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749 [TBL] [Abstract][Full Text] [Related]
7. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis. Sokoloski JA; Beardsley GP; Sartorelli AC Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277 [TBL] [Abstract][Full Text] [Related]
9. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid. Sokoloski JA; Beardsley GP; Sartorelli AC Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415 [TBL] [Abstract][Full Text] [Related]
10. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase. Chong LK; Tattersall MH Biochem Pharmacol; 1995 Mar; 49(6):819-27. PubMed ID: 7702640 [TBL] [Abstract][Full Text] [Related]
11. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626 [TBL] [Abstract][Full Text] [Related]
12. Quantitation of folic acid enhancement of antifolate synergism. Gaumont Y; Kisliuk RL; Parsons JC; Greco WR Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766 [TBL] [Abstract][Full Text] [Related]
13. Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets. Pohland RC; Alati T; Lantz RJ; Grindey GB J Pharm Sci; 1994 Oct; 83(10):1396-9. PubMed ID: 7884657 [TBL] [Abstract][Full Text] [Related]
14. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196 [TBL] [Abstract][Full Text] [Related]
15. Evidence for a relationship between intracellular GTP levels and the induction of HL-60 leukemia cell differentiation by 5,10-dideazatetrahydrofolic acid (DDATHF). Sokoloski JA; Pizzorno G; Beardsley GP; Sartorelli AC Oncol Res; 1993; 5(8):293-9. PubMed ID: 8012061 [TBL] [Abstract][Full Text] [Related]
16. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines. Pizzorno G; Sokoloski JA; Cashmore AR; Moroson BA; Cross AD; Beardsley GP Mol Pharmacol; 1991 Jan; 39(1):85-9. PubMed ID: 1702876 [TBL] [Abstract][Full Text] [Related]
17. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. Beardsley GP; Moroson BA; Taylor EC; Moran RG J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524 [TBL] [Abstract][Full Text] [Related]
18. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels. Lehman NL Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)5,10-dideazatetrahydrofolic acid. Pizzorno G; Davis SJ; Hartigan DJ; Russello O Biochem Pharmacol; 1994 Jun; 47(11):1981-8. PubMed ID: 7516657 [TBL] [Abstract][Full Text] [Related]
20. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Bronder JL; Moran RG Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]